Zhang Shuai, Zhang Yu, Liu Min, Tao Xincao, Xie Wanmu, Wan Jun, Zhai Zhenguo
Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Pulm Circ. 2021 Jan 7;11(1):2045894020940537. doi: 10.1177/2045894020940537. eCollection 2021 Jan-Mar.
Pulmonary artery sarcoma is a rare malignancy with poor prognosis. Lack of specific clinical manifestations, some patients are even confirmed postoperatively or at autopsy, that leads to the delay in treatment. Early diagnosis and radical surgical resection provide the possibility of prolonged survival. We retrospectively enrolled 13 patients diagnosed with pulmonary artery sarcoma at our hospital between 2015 and 2019. Their clinical, laboratory, radiological, and histopathological data were collected and analyzed. Published case series were also reviewed. Results show that, the median age of the patients was 53 years, with 6 (46.2%) males. The most common symptom is exertional dyspnea. Erythrocyte sedimentation rate and C-reactive protein were increased in 76.9% and 69.2% of these patients, while D-Dimer remained normal or elevated slightly. Metastasis was present at diagnosis in eight (61.5%) patients. Ten patients were diagnosed histologically: three were diagnosed after pulmonary endarterectomy, four by endobronchial ultrasound-guided transbronchial needle aspiration, two by percutaneous lung biopsy, and one by endovascular aspiration biopsy. Four patients underwent surgery and one is waiting for surgery. Nine patients received chemotherapy; and three of them received targeted therapy with anlotinib after chemotherapy. Two patients received anti-PD-1 monoclonal antibody. One patient died during endobronchial ultrasound-guided transbronchial needle aspiration. Two patients died 9 and 13 months after diagnosis, respectively; one refused invasive diagnostic procedures and died three months after clinical diagnosis. In conclusion, the most appropriate approach to get tissue specimen needs to be tailored to every pulmonary artery sarcoma patient. Pulmonary endarterectomy combined with chemotherapy and targeted therapy has prolonged their survival time.
肺动脉肉瘤是一种罕见的恶性肿瘤,预后较差。由于缺乏特异性临床表现,部分患者甚至在术后或尸检时才得以确诊,从而导致治疗延误。早期诊断和根治性手术切除为延长生存期提供了可能。我们回顾性纳入了2015年至2019年间在我院诊断为肺动脉肉瘤的13例患者。收集并分析了他们的临床、实验室、影像学和组织病理学数据。同时也对已发表的病例系列进行了回顾。结果显示,患者的中位年龄为53岁,男性6例(46.2%)。最常见的症状是劳力性呼吸困难。这些患者中76.9%的红细胞沉降率和69.2%的C反应蛋白升高,而D-二聚体保持正常或略有升高。8例(61.5%)患者在诊断时已有转移。10例患者经组织学诊断:3例在肺动脉内膜剥脱术后确诊,4例通过支气管内超声引导下经支气管针吸活检确诊,2例通过经皮肺活检确诊,1例通过血管内抽吸活检确诊。4例患者接受了手术,1例正在等待手术。9例患者接受了化疗;其中3例在化疗后接受了安罗替尼靶向治疗。2例患者接受了抗PD-1单克隆抗体治疗。1例患者在支气管内超声引导下经支气管针吸活检过程中死亡。2例患者分别在诊断后9个月和13个月死亡;1例拒绝侵入性诊断检查,在临床诊断后3个月死亡。总之,获取组织标本的最合适方法需要根据每例肺动脉肉瘤患者的情况进行调整。肺动脉内膜剥脱术联合化疗和靶向治疗延长了他们的生存时间。